Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 6—June 2004
Research

Antimicrobial Resistance among Campylobacter Strains, United States, 1997–2001

Amita Gupta*Comments to Author , Jennifer M. Nelson*, Timothy J. Barrett*, Robert V. Tauxe*, Shannon P. Rossiter*, Cindy R. Friedman*, Kevin W. Joyce*, Kirk E. Smith†, Timothy F. Jones‡, Marguerit A. Hawkins§, Beletshachew Shiferaw¶, James L. Beebe#, Duc J. Vugia**, Terry Rabatsky-Ehr††, James A. Benson‡‡, Timothy P. Root§§, Frederick J. Angulo*, and for the NARMS Working Group
Author affiliations: *Centers for Disease Control, Atlanta, Georgia, USA; †Minnesota Department of Health, St. Paul, Minnesota, USA; ‡Tennessee Department of Health, Nashville, Tennessee, USA; §Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA; ¶Oregon Department of Human Services, Portland, Oregon, USA; #Colorado Department of Public Health & Environment, Denver, Colorado, USA; **California Department of Health Services, Sacramento, California, USA; ††Connecticut Department of Public Health, Hartford, Connecticut, USA; ‡‡Georgia Department of Human Services, Atlanta, Georgia, USA; §§New York State Department of Health, Albany, New York, USA

Main Article

Figure 2

Quinolone- and fluoroquinolone-resistant Campylobacter jejuni in the United States, 1982–2001. FQ, fluoroquinolone; MN, Minnesota quinolone resistance among C. jejuni strains data (adapted from 18) NARMS, National Antimicrobial Resistance Monitoring System. Prior survey data adapted from reference 19 and 30.

Figure 2. Quinolone- and fluoroquinolone-resistant Campylobacter jejuni in the United States, 1982–2001. FQ, fluoroquinolone; MN, Minnesota quinolone resistance among C. jejuni strains data (adapted from 18) NARMS, National Antimicrobial Resistance Monitoring System. Prior survey data adapted from reference 19 and 30.

Main Article

References
  1. Mead  PS, Slutsker  L, Dietz  V, McCaig  LF, Bresee  JS, Shapiro  C, Food-related illness and death in the United States. Emerg Infect Dis. 1999;5:60725. DOIPubMed
  2. Centers for Disease Control and Prevention. Preliminary FoodNet data on the incidence of foodborne illnesses—selected sites, United States, 2002. MMWR Morb Mortal Wkly Rep. 2003;52:3403.PubMed
  3. Altekruse  SF, Stern  NJ, Fields  PI, Swerdlow  DL. Campylobacter jejuni—an emerging foodborne pathogen. Emerg Infect Dis. 1999;5:2835. DOIPubMed
  4. Allos  BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis. 2001;32:12016. DOIPubMed
  5. Salazar-Lindo  E, Sack  RB, Chea-Woo  E, Kay  BA, Piscoya  ZA, Leon-Barua  R, Early treatment with erythromycin of Campylobacter jejuni–associated dysentery in children. J Pediatr. 1986;109:35560. DOIPubMed
  6. Goodman  LJ, Trenholme  GM, Kaplan  RL, Segreti  J, Hines  D, Petrak  R, Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med. 1990;150:5416. DOIPubMed
  7. Mattila  L, Peltola  H, Siitonen  A, Kyronseppa  H, Simula  I, Kataja  M. Short-term treatment of traveler’s diarrhea with norfloxacin: a double- blind, placebo-controlled study during two seasons. Clin Infect Dis. 1993;17:77982.PubMed
  8. Dryden  MS, Gabb  RJ, Wright  SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis. 1996;22:101925.PubMed
  9. The choice of antibacterial drugs. Med Lett Drugs Ther. 1988;▪▪▪:3342.PubMed
  10. Endtz  HP, Mouton  RP, van der Reyden  T, Ruijs  GJ, Biever  M, van Klingeren  B. Fluoroquinolone resistance in Campylobacter spp isolated from human stools and poultry products. [see comments]. Lancet. 1990;335:787. DOIPubMed
  11. Gaunt  PN, Piddock  LJ. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother. 1996;37:74757. DOIPubMed
  12. Prats  G, Mirelis  B, Llovet  T, Munoz  C, Miro  E, Navarro  F. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985–1987 and 1995–1998 in Barcelona. Antimicrob Agents Chemother. 2000;44:11405. DOIPubMed
  13. Engberg  J, Aarestrup  FM, Taylor  DE, Gerner-Smidt  P, Nachamkin  I. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis. 2001;7:2434. DOIPubMed
  14. Harris  NV, Thompson  D, Martin  DC, Nolan  CM. A survey of Campylobacter and other bacterial contaminants of pre-market chicken and retail poultry and meats, King County, Washington. Am J Public Health. 1986;76:4016. DOIPubMed
  15. Adak  GK, Cowden  JM, Nicholas  S, Evans  HS. The Public Health Laboratory Service national case-control study of primary indigenous sporadic cases of Campylobacter infection. Epidemiol Infect. 1995;115:1522. DOIPubMed
  16. Eberhart-Phillips  J, Walker  N, Garrett  N, Bell  D, Sinclair  D, Rainger  W, Campylobacteriosis in New Zealand: results of a case-control study. J Epidemiol Community Health. 1997;51:68691. DOIPubMed
  17. U.S. Food and Drug Administration. Enrofloxacin for poultry; opportunity for Hearing. [cited 2002 Nov 18]. Available from: http://www.fda.gov/OHRMS/DOCKETS/98fr/103100a.htm. DHHS; 2000
  18. Smith  KE, Besser  JM, Hedberg  CW, Leano  FT, Bender  JB, Wicklund  JH, Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. N Engl J Med. 1999;340:152532. DOIPubMed
  19. Tenover  FC, Baker  CN, Fennell  CL, Ryan  CA. Antimicrobial resistance in Campylobacter species. In: Nachamkin I, Blaser MJ, Tompkins LS, editors. Campylobacter jejuni current status and future trends. Washington: American Society of Microbiology; 1992. p. 66–73.
  20. Patton  CM, Nicholson  MA, Ostroff  SM, Ries  AA, Wachsmuth  IK, Tauxe  RV. Common somatic O and heat-labile serotypes among Campylobacter strains from sporadic infections in the United States. J Clin Microbiol. 1993;31:152530.PubMed
  21. Barrett  TJ, Patton  CM, Morris  GK. Differentiation of Campylobacter species using phenotypic characterization. Lab Med. 1988;19:96102.
  22. Murray  PR. Manual of clinical microbiology. In: Microbiology. 7th ed. Washington: ASM Press; 1999. p. 1773.
  23. Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System Annual Report 2001. Atlanta: Department of Health and Human Services. [cited 2003 Nov]. Available from: http://www.cdc.gov/narms/annual/2001/annual_01.htm
  24. Linton  D, Lawson  AJ, Owen  RJ, Stanley  J. PCR detection, identification to species level, and fingerprinting of Campylobacter jejuni and Campylobacter coli direct from diarrheic samples. J Clin Microbiol. 1997;35:256872.PubMed
  25. Gonzalez  I, Grant  KA, Richardson  PT, Park  SF, Collins  MD. Specific identification of the enteropathogens Campylobacter jejuni and Campylobacter coli by using a PCR test based on the ceuE gene encoding a putative virulence determinant. J Clin Microbiol. 1997;35:75963.PubMed
  26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: eighth informational supplement. Wayne (PA): The Committee; 1998.
  27. Hunt  JM. Campylobacter. In: Food and Drug Administration bacteriological analytical manual. 7th ed. Arlington (VA): AOAC International; 1992. p. 77–91.
  28. Lastovica  A, Skirrow  M. Clinical significance of Campylobacter and related species other than Campylobacter jejuni and C. coli. In: Blaser M, editor. Campylobacter. Washington: American Society for Microbiology; 2000. p. 89–120.
  29. Nachamkin  I, Ung  H, Li  M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982–2001. Emerg Infect Dis. 2002;8:1501–3. Nachamkin I. Antimicrobial susceptibility of Campylobacter jejuni and Campylobacter coli to ciprofloxacin, erythromycin and tetracycline from 1982 to 1992. Med Microbiol Lett. 1994;3:3005.
  30. Kiehlbauch  J, Simon  M, Makowski  J. Use of filtration to isolate Campylobacter and related organisms from stools. In: Newell DG, editor. Campylobacters, Helicobacters, and related organisms. New York: Plenum Press; 1996. p. 47–9.
  31. McCaig  LF, Besser  RE, Hughes  JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992–2000. Emerg Infect Dis. 2003;9:4327.PubMed
  32. Marano  NVD, Fiorentino  T, Segler  S, Carter  M, Kassenborg  H, Smith  K, Fluoroquinolone-resistant Campylobacter causes longer duration of diarrhea than fluoroquinolone-susceptible Campylobacter strains in FoodNet sites. 2nd International Conference on Emerging Infectious Diseases. Atlanta, GA, 2000.
  33. Kuschner  RA, Trofa  AF, Thomas  RJ, Hoge  CW, Pitarangsi  C, Amato  S, Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis. 1995;21:53641.PubMed
  34. Kassenbourg  H, Smith  K, Vugia  D, Rabatsky-Ehr  T, Bates  M, Dumas  N, Fluoroquinolone-resistant infections: eating poultry outside the home and foreign travel are risk factors. Clin Infect Dis. 2004. In press. DOI
  35. Zhao  C, Ge  B, De Villena  J, Sudler  R, Yeh  E, Zhao  S, Prevalence of Campylobacter spp., Escherichia coli, and Salmonella serovars in retail chicken, turkey, pork, and beef from the greater Washington, D.C. area. Appl Environ Microbiol. 2001;67:54316. DOIPubMed
  36. Ge  B, White  DG, McDermott  PF, Girard  W, Zhao  S, Hubert  S, Antimicrobial-resistant Campylobacter species from retail raw meats. Appl Environ Microbiol. 2003;69:30057. DOIPubMed
  37. Animal Health Institute. Antimicrobial volume survey. [cited 2002 Dec 12]. Available from: www.ahi.org
  38. McDermott  PF, Bodeis  SM, English  LL, White  DG, Walker  RD, Zhao  S, Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones. J Infect Dis. 2002;185:83740. DOIPubMed
  39. Endtz  HP, Ruijs  GJ, van Klingeren  B, Jansen  WH, van der Reyden  T, Mouton  RP. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother. 1991;27:199208. DOIPubMed
  40. Bager  F, Emborg  H, Heuer  O. DANMAP 2001—Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. Vol. 2002. Copenhagen: Statens Serum Institut; 2001.
  41. U.S. Food and Drug Administration. The human health impact of fluoroquinolone-resistant Campylobacter attributed to the consumption of chicken. [cited 2002 15 Jun]. Available from: http://www.fda.gov/cvm/antimicrobial/revisedRA.pdf
  42. FDA withdraws approval of two poultry drugs. FDA Consum. 2001;35:5.PubMed
  43. Baker  CN. The E-test and Campylobacter jejuni. Diagn Microbiol Infect Dis. 1992;15:46972. DOIPubMed

Main Article

1This isolate was reported to be ciprofloxacin resistant in reference

Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external